menu

ReachMD

Be part of the knowledge.™
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Shifting Paradigms for Assessment and Management of Lower-Risk Myelodysplastic Syndromes: Genomics, Risk Stratification, and Novel Therapies

4 chapters
Play All
1.00 credits
60 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related

  • Overview

    Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms associated with cytopenias, suboptimal production of mature erythrocytes, and substantial risk for progression to acute myeloid leukemia.

    The classification of MDS and MDS/myeloproliferative neoplasm (MPN) overlap syndromes continue to evolve, making them difficult for clinicians to define and raising important new considerations for diagnosis, assessment, risk stratification, and treatment. The presence of ring sideroblasts (RS) and mutations in the SF3B1 gene correlate with favorable outcomes and help define specific disease subtypes.

    In this video-based educational activity, an interview-style expert faculty panel will provide their perspectives and insights on the latest trends and emerging research in low-risk MDS, including guideline-directed diagnostic workup, RS evaluation and SF3B1 testing and their implications, currently approved and novel emerging treatment strategies for managing lower risk MDS, and strategies to mitigate and manage treatment-related adverse events.

  • Disclosure of Conflicts of Interest

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies.  An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by  or on patients. All relevant conflicts of interest are identified  and mitigated prior to initiation of the planning phase for an activity. 

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

    Rami Komrokji, MD, reported a financial interest/relationship or affiliation in the form of Consultant: AbbVie; Acceleron Pharma; Bristol-Myers Squibb Co; Celgene Corp; CTI BioPharma Corp; Geron; Innovent; Jazz Pharmaceuticals plc; Novartis Pharmaceuticals Corp; PharmaEssentia; Taiho Pharmaceutical Co, Ltd; and Takeda. Speaker: AbbVie, Bristol-Myers Squibb Co, Celgene Corp, Jazz Pharmaceuticals plc, and Servier.

    Michael R. Savona, MD, reported a financial interest/relationship or affiliation in the form of Consultant: AbbVie; Bristol-Myers Squibb Co; Celgene Corp; CTI BioPharma; Geron; Novartis Pharmaceuticals Corp; Ryvu; Sierra Oncology; Takeda; and TG Therapeutics, Inc. Research funding: ALX Oncology; Astex; Incyte; Takeda; and TG Therapeutics, Inc. Royalty shares: Boehringer-Ingelheim. Stocks: Karyopharm and Ryvu.

    Jamile M. Shammo, MD, FASCP, FACP reported a financial interest /relationship or affiliation in the form of Speakers' bureau: Alexion, Bristol-Myers Squibb Co, Incyte, and Sanofi. Research grant: AbbVie, Alexion, Bristol-Myers Squibb Company, CTI BioPharma, and Kartos Therapeutics. Data and safety monitoring committee: Apellis Pharmaceuticals and NS-Pharma. Stocks: AbbVie, Baxter, and Takeda Pharmaceutical Co.

    The directors, planners, managers, and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:  Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman,  PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; Melissa Duffy, PA-C; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.

  • Target Audience

    This educational initiative is designed for hematologists, heme-oncologists, medical oncologists, pathologists, hematopathologists, lab professionals, advanced practitioners, and other healthcare professionals who are part of the interprofessional team responsible for the therapeutic management of patients with lower-risk MDS and symptomatic anemia.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    1. Interpret molecular testing and risk stratification to facilitate diagnosis, prognostication, and treatment decision-making of MDS
    2. Formulate an evidence-based treatment plan for patients with lower-risk MDS based on patient- and disease-related factors
    3. Assess recent and available clinical evidence for novel emerging treatment strategies for managing lower-risk MDS
    4. Employ strategies to mitigate and manage treatment-related adverse events to enhance quality of life for patients with MDS

  • Accreditation and Credit Designation Statements

    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. 



    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits.  Approval is valid until 08/30/2023 PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This application-based activity is approved for 1.0 contact hours of continuing pharmacy education JA4008106-0000-22-033-H01-P. 

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hours.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    Laboratory Professionals
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 1.0 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    Provided by: 

  • Commercial Support

    This activity is supported by an educational grant from Bristol-Myers Squibb Company

  • Method of Participation and Request for Credit:

    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Presenters

Related

  • Shifting Paradigms for Assessment and Management of Lower Risk Myelodysplastic Syndromes Transcript

    Shifting Paradigms for Assessment and Management of Lower-Risk Myelodysplastic Syndromes - Transcript

    Show more
  • Shifting Paradigms for Assessment and Management of Lower Risk Myelodysplastic Syndromes Slides

    Shifting Paradigms for Assessment and Management of Lower-Risk Myelodysplastic Syndromes - Slides

    Show more
Recommended
Details
Presenters
Related

Recommended

  • Overview

    Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms associated with cytopenias, suboptimal production of mature erythrocytes, and substantial risk for progression to acute myeloid leukemia.

    The classification of MDS and MDS/myeloproliferative neoplasm (MPN) overlap syndromes continue to evolve, making them difficult for clinicians to define and raising important new considerations for diagnosis, assessment, risk stratification, and treatment. The presence of ring sideroblasts (RS) and mutations in the SF3B1 gene correlate with favorable outcomes and help define specific disease subtypes.

    In this video-based educational activity, an interview-style expert faculty panel will provide their perspectives and insights on the latest trends and emerging research in low-risk MDS, including guideline-directed diagnostic workup, RS evaluation and SF3B1 testing and their implications, currently approved and novel emerging treatment strategies for managing lower risk MDS, and strategies to mitigate and manage treatment-related adverse events.

  • Disclosure of Conflicts of Interest

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies.  An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by  or on patients. All relevant conflicts of interest are identified  and mitigated prior to initiation of the planning phase for an activity. 

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

    Rami Komrokji, MD, reported a financial interest/relationship or affiliation in the form of Consultant: AbbVie; Acceleron Pharma; Bristol-Myers Squibb Co; Celgene Corp; CTI BioPharma Corp; Geron; Innovent; Jazz Pharmaceuticals plc; Novartis Pharmaceuticals Corp; PharmaEssentia; Taiho Pharmaceutical Co, Ltd; and Takeda. Speaker: AbbVie, Bristol-Myers Squibb Co, Celgene Corp, Jazz Pharmaceuticals plc, and Servier.

    Michael R. Savona, MD, reported a financial interest/relationship or affiliation in the form of Consultant: AbbVie; Bristol-Myers Squibb Co; Celgene Corp; CTI BioPharma; Geron; Novartis Pharmaceuticals Corp; Ryvu; Sierra Oncology; Takeda; and TG Therapeutics, Inc. Research funding: ALX Oncology; Astex; Incyte; Takeda; and TG Therapeutics, Inc. Royalty shares: Boehringer-Ingelheim. Stocks: Karyopharm and Ryvu.

    Jamile M. Shammo, MD, FASCP, FACP reported a financial interest /relationship or affiliation in the form of Speakers' bureau: Alexion, Bristol-Myers Squibb Co, Incyte, and Sanofi. Research grant: AbbVie, Alexion, Bristol-Myers Squibb Company, CTI BioPharma, and Kartos Therapeutics. Data and safety monitoring committee: Apellis Pharmaceuticals and NS-Pharma. Stocks: AbbVie, Baxter, and Takeda Pharmaceutical Co.

    The directors, planners, managers, and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:  Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman,  PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; Melissa Duffy, PA-C; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.

  • Target Audience

    This educational initiative is designed for hematologists, heme-oncologists, medical oncologists, pathologists, hematopathologists, lab professionals, advanced practitioners, and other healthcare professionals who are part of the interprofessional team responsible for the therapeutic management of patients with lower-risk MDS and symptomatic anemia.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    1. Interpret molecular testing and risk stratification to facilitate diagnosis, prognostication, and treatment decision-making of MDS
    2. Formulate an evidence-based treatment plan for patients with lower-risk MDS based on patient- and disease-related factors
    3. Assess recent and available clinical evidence for novel emerging treatment strategies for managing lower-risk MDS
    4. Employ strategies to mitigate and manage treatment-related adverse events to enhance quality of life for patients with MDS

  • Accreditation and Credit Designation Statements

    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. 



    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits.  Approval is valid until 08/30/2023 PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This application-based activity is approved for 1.0 contact hours of continuing pharmacy education JA4008106-0000-22-033-H01-P. 

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hours.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    Laboratory Professionals
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 1.0 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    Provided by: 

  • Commercial Support

    This activity is supported by an educational grant from Bristol-Myers Squibb Company

  • Method of Participation and Request for Credit:

    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Presenters

Related

  • Shifting Paradigms for Assessment and Management of Lower Risk Myelodysplastic Syndromes Transcript

    Shifting Paradigms for Assessment and Management of Lower-Risk Myelodysplastic Syndromes - Transcript

    Show more
  • Shifting Paradigms for Assessment and Management of Lower Risk Myelodysplastic Syndromes Slides

    Shifting Paradigms for Assessment and Management of Lower-Risk Myelodysplastic Syndromes - Slides

    Show more
Schedule29 May 2023
PrevNext

Program Chapters

Segment Chapters

Playlist:

Recommended